EMBLEM™ S-ICD System
Subcutaneous Implantable Defibrillator
Modular CRM (mCRM™) System
MODULAR ATP Trial
The MODULAR ATP trial is the pivotal study evaluating the safety and performance of the mCRM™ System. It includes patients implanted with EMBLEM™ S-ICD and EMPOWER™ LP.
6-Month Results (2024):
- 97.5% major complication-free rate (goal ≥86%)
- 98.8% wireless communication success (goal ≥88%)
- 97.4% pacing capture thresholds ≤2 V @ 0.4 ms (goal ≥80%)
- 61.3% ATP success in treated episodes
- 0% ATP-related discomfort reported by patients
Pre-Clinical & Technical Validation
See the pre-clinical data evaluating the use of modular CRM technology in animal subjects.
Discover the Next Evolution in S-ICD Therapy
Explore how the EMBLEM™ S-ICD System now fits into Boston Scientific’s modular CRM platform, by offering patients life-saving defibrillation today, with the flexibility to add leadless pacing if needed tomorrow.